Cassava Sciences Inc Financial Statements (SAVA)
|
|
|
|
Report date
|
|
|
26.03.2020 |
23.03.2021 |
01.03.2022 |
28.02.2023 |
28.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.002 |
0.000 |
|
2.35 |
|
Operating Income, bln rub |
|
|
-4.96 |
-6.45 |
-32.9 |
-80.0 |
-106.0 |
|
-140.5 |
|
EBITDA, bln rub |
? |
|
-4.57 |
-6.31 |
-31.9 |
-74.9 |
-95.7 |
|
-133.5 |
|
Net profit, bln rub |
? |
|
-4.25 |
-5.85 |
-31.8 |
-72.5 |
-97.2 |
|
-17.7 |
|
|
OCF, bln rub |
? |
|
-2.51 |
-5.38 |
-30.2 |
-77.5 |
-82.0 |
|
-78.0 |
|
CAPEX, bln rub |
? |
|
0.018 |
0.000 |
22.2 |
2.71 |
0.414 |
|
0.087 |
|
FCF, bln rub |
? |
|
-2.53 |
-5.38 |
-52.4 |
-80.2 |
-82.4 |
|
-78.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
4.96 |
6.79 |
32.9 |
80.0 |
106.0 |
|
139.6 |
|
Cost of production, bln rub |
|
|
0.058 |
0.346 |
0.534 |
1.30 |
89.4 |
|
0.967 |
|
R&D, bln rub |
|
|
1.57 |
3.05 |
24.8 |
68.0 |
89.4 |
|
67.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
2.63 |
|
|
Assets, bln rub |
|
|
23.5 |
94.3 |
266.8 |
234.8 |
151.7 |
|
223.8 |
|
Net Assets, bln rub |
? |
|
22.1 |
92.2 |
253.9 |
227.5 |
137.5 |
|
166.6 |
|
Debt, bln rub |
|
|
0.090 |
0.293 |
0.236 |
0.139 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
23.1 |
93.5 |
233.4 |
201.0 |
121.1 |
|
149.0 |
|
Net debt, bln rub |
|
|
-23.0 |
-93.2 |
-233.2 |
-200.9 |
-121.1 |
|
-149.0 |
|
|
Ordinary share price, rub |
|
|
5.20 |
6.82 |
43.7 |
29.5 |
22.5 |
|
25.8 |
|
Number of ordinary shares, mln |
|
|
17.4 |
26.1 |
39.4 |
40.2 |
41.9 |
|
48.0 |
|
|
Market cap, bln rub |
|
|
91 |
178 |
1 722 |
1 188 |
944 |
|
1 235 |
|
EV, bln rub |
? |
|
68 |
85 |
1 489 |
987 |
823 |
|
1 086 |
|
Book value, bln rub |
|
|
22 |
92 |
253 |
227 |
137 |
|
167 |
|
|
EPS, rub |
? |
|
-0.24 |
-0.22 |
-0.81 |
-1.80 |
-2.32 |
|
-0.37 |
|
FCF/share, rub |
|
|
-0.15 |
-0.21 |
-1.33 |
-2.00 |
-1.97 |
|
-1.63 |
|
BV/share, rub |
|
|
1.27 |
3.53 |
6.42 |
5.64 |
3.27 |
|
3.47 |
|
|
EBITDA margin, % |
? |
|
|
|
|
-4 163 611% |
|
|
-5 686% |
|
Net margin, % |
? |
|
|
|
|
-4 026 222% |
|
|
-752.3% |
|
FCF yield, % |
? |
|
-2.80% |
-3.02% |
-3.04% |
-6.76% |
-8.73% |
|
-6.32% |
|
ROE, % |
? |
|
-19.2% |
-6.35% |
-12.5% |
-31.9% |
-70.7% |
|
-10.6% |
|
ROA, % |
? |
|
-18.1% |
-6.21% |
-11.9% |
-30.9% |
-64.1% |
|
-7.89% |
|
|
P/E |
? |
|
-21.3 |
-30.4 |
-54.1 |
-16.4 |
-9.71 |
|
-69.9 |
|
P/FCF |
|
|
-35.8 |
-33.1 |
-32.9 |
-14.8 |
-11.4 |
|
-15.8 |
|
P/S |
? |
|
|
|
|
659 759 |
|
|
526.1 |
|
P/BV |
? |
|
4.10 |
1.93 |
6.81 |
5.23 |
6.88 |
|
7.42 |
|
EV/EBITDA |
? |
|
-14.8 |
-13.4 |
-46.7 |
-13.2 |
-8.60 |
|
-8.14 |
|
Debt/EBITDA |
|
|
5.03 |
14.8 |
7.32 |
2.68 |
1.27 |
|
1.12 |
|
|
R&D/CAPEX, % |
|
|
8 711% |
|
111.7% |
2 509% |
21 600% |
|
77 975% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
150 667% |
|
|
3.71% |
|
| Cassava Sciences Inc shareholders |
